US5019761049
US5019761049
Kyverna Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 |
|---|---|---|---|
Market & Enterprise Value | |||
Market Cap | 395.18M EUR | 548.59M EUR | 522.4M EUR |
Enterprise Value | 215.76M EUR | 549.78M EUR | 523.96M EUR |
Valuation Multiples | |||
Trailing P/E | -- | -- | -- |
Forward P/E | -2.02x | -- | -- |
Price to Sales | -- | -- | -- |
Price to Book | 2.38x | 3.31x | 2.67x |
EV/Revenue | -- | -- | -- |
EV/EBITDA | -1.37x | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- |
EV/FCF | -- | -- | -- |
FCF Yield | -27.25% | -29.21% | -29.01% |